't zal maar gebeuren schreef op 2 december 2015 14:08:
14:05:02 / 02-12-15 Zafgen Says Another Patient Dies in Beloranib Study
Zafgen Inc. said Wednesday that another patient died during a continuing study of a rare genetic disorder, two months after U.S. regulators temporarily halted its clinical trial to investigate circumstances surrounding the previous death.
Shares, which closed Tuesday at $15.93, were down 43% in premarket trading.
The biopharmaceutical company said it learned Tuesday that a patient being treated with beloranib for Prader-Willi syndrome was diagnosed with bilateral pulmonary emboli—blood clots to the lung—and died.
The patient was receiving the drug during the open-label extension portion of the phase 3 trial.
In October, Zafgen disclosed that a patient had died during the belanorib study. The U.S. Food and Drug Administration placed beloranib on partial clinical hold because of the thromboembolic events—blood clots that move after forming and block other vessels—in other trials of beloranib and the unknown nature of that death.
On Tuesday, Chief Executive Thomas Hughes said Zafgen is in talks with the FDA while determining next steps for the program.
"Our thoughts are with the patient and their family at this time," he said. "Patient safety remains our top priority and we are investigating the circumstances around this event."
The company reiterated its expectation for "top-line results" of the randomized portion of the clinical trial in the first quarter of 2016.
Write to Anne Steele at Anne.Steele@wsj.com
Subscribe to WSJ:
online.wsj.com?mod=djnwires(END) Dow Jones Newswires
December 02, 2015 08:05 ET (13:05 GMT)
© 2015 Dow Jones & Company, Inc.
ZAFGEN INC.
US98885E1038